Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2009 4
2016 1
2017 3
2018 4
2019 4
2020 7
2021 7
2022 4
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Sands BE, et al. N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. N Engl J Med. 2019. PMID: 31553834 Clinical Trial.
Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease.
Macaluso FS, Grova M, Mocciaro F, Di Mitri R, Privitera AC, Distefano ME, Vitello A, Camilleri S, Ferracane C, Pluchino D, Belluardo N, Giangreco E, Fries W, Viola A, Cappello M, D'Amato L, Bertolami C, Ventimiglia M, Renna S, Casà A, D'Antonio E, De Vivo S, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Macaluso FS, et al. Among authors: privitera ac. J Gastroenterol Hepatol. 2023 Sep;38(9):1503-1509. doi: 10.1111/jgh.16208. Epub 2023 May 6. J Gastroenterol Hepatol. 2023. PMID: 37148148
The 1st EoETALY Consensus on the Diagnosis and Management of Eosinophilic Esophagitis - Definition, Clinical Presentation and Diagnosis.
de Bortoli N, Visaggi P, Penagini R, Annibale B, Baiano Svizzero F, Barbara G, Bartolo O, Battaglia E, Di Sabatino A, De Angelis P, Docimo L, Frazzoni M, Furnari M, Iori A, Iovino P, Lenti MV, Marabotto E, Marasco G, Mauro A, Oliva S, Pellegatta G, Pesce M, Privitera AC, Puxeddu I, Racca F, Ribolsi M, Ridolo E, Russo S, Sarnelli G, Tolone S, Zentilin P, Zingone F, Barberio B, Ghisa M, Savarino EV. de Bortoli N, et al. Among authors: privitera ac. Dig Liver Dis. 2024 Feb 28:S1590-8658(24)00265-2. doi: 10.1016/j.dld.2024.02.005. Online ahead of print. Dig Liver Dis. 2024. PMID: 38423918
Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease.
Macaluso FS, Cappello M, Crispino F, Grova M, Privitera AC, Piccillo G, Magnano A, Ferracane C, Belluardo N, Giangreco E, Fries W, Viola A, Di Mitri R, Mocciaro F, Camilleri S, Garufi S, Renna S, Casà A, Maida M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Macaluso FS, et al. Among authors: privitera ac. Dig Liver Dis. 2022 May;54(5):629-634. doi: 10.1016/j.dld.2021.11.021. Epub 2021 Dec 16. Dig Liver Dis. 2022. PMID: 34924320
The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn's disease.
Macaluso FS, Grova M, Saladino M, Cappello M, Demarzo MG, Privitera AC, Giangreco E, Garufi S, Renna S, Casà A, Ventimiglia M, Fries W, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Macaluso FS, et al. Among authors: privitera ac. Dig Liver Dis. 2023 Apr;55(4):471-477. doi: 10.1016/j.dld.2022.08.028. Epub 2022 Sep 17. Dig Liver Dis. 2023. PMID: 36127230
Severe Activity of Inflammatory Bowel Disease is a Risk Factor for Severe COVID-19.
Macaluso FS, Giuliano A, Fries W, Viola A, Abbruzzese A, Cappello M, Giuffrida E, Carrozza L, Privitera AC, Magnano A, Ferracane C, Scalisi G, Minissale MG, Giangreco E, Garufi S, Bertolami C, Cucinotta U, Graziano F, Casà A, Renna S, Teresi G, Rizzuto G, Mannino M, Maida M, Orlando A. Macaluso FS, et al. Among authors: privitera ac. Inflamm Bowel Dis. 2023 Feb 1;29(2):217-221. doi: 10.1093/ibd/izac064. Inflamm Bowel Dis. 2023. PMID: 35385102 Free PMC article.
Use of the masseteric nerve to treat segmental midface paresis.
Biglioli F, Soliman M, El-Shazly M, Saadeldeen W, Abda EA, Allevi F, Rabbiosi D, Tarabbia F, Lozza A, Cupello S, Privitera A, Dell'Aversana Orabona G, Califano L. Biglioli F, et al. Among authors: privitera a. Br J Oral Maxillofac Surg. 2018 Oct;56(8):719-726. doi: 10.1016/j.bjoms.2018.07.023. Epub 2018 Aug 16. Br J Oral Maxillofac Surg. 2018. PMID: 30122622
Surgical treatment of synkinesis between smiling and eyelid closure.
Biglioli F, Kutanovaite O, Rabbiosi D, Colletti G, Mohammed MAS, Saibene AM, Cupello S, Privitera A, Battista VMA, Lozza A, Allevi F. Biglioli F, et al. Among authors: privitera a. J Craniomaxillofac Surg. 2017 Dec;45(12):1996-2001. doi: 10.1016/j.jcms.2017.09.008. Epub 2017 Sep 18. J Craniomaxillofac Surg. 2017. PMID: 29033208
A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease.
Macaluso FS, Ventimiglia M, Fries W, Viola A, Sitibondo A, Cappello M, Scrivo B, Busacca A, Privitera AC, Camilleri S, Garufi S, Di Mitri R, Mocciaro F, Belluardo N, Giangreco E, Bertolami C, Renna S, Orlando R, Rizzuto G, Cottone M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Macaluso FS, et al. Among authors: privitera ac. J Gastroenterol Hepatol. 2021 Jan;36(1):105-111. doi: 10.1111/jgh.15107. Epub 2020 Jun 8. J Gastroenterol Hepatol. 2021. PMID: 32428981
34 results